Physician profile
Mark A Rountree
NPI 1265414775
$2,615.37
in general payments reported to CMS, 2019-2025
16 companies · $662 in 2025
The $662 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $422 · 2023: $694 · 2024: $645 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $623.62 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $527.68 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $387.94 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Novartis Pharmaceuticals Corporation | $220.34 | 2023-2025 | |
| Grifols USA, LLC | $191.22 | 2022-2024 | Xembify |
| Biocryst US Sales Co., LLC | $145.89 | 2023-2025 | Orladeyo |
| Amgen INC. | $141.88 | 2022-2023 | Tezspire |
| Genentech USA, INC. | $113.33 | 2023-2025 | Xolair |
| Pfizer INC. | $54.29 | 2021-2022 | |
| Leo Pharma INC. | $40.95 | 2023-2024 | Adbry |
| Glaxosmithkline, LLC. | $40.17 | 2024 | Nucala |
| Astrazeneca Pharmaceuticals LP | $32.45 | 2023-2025 | Tezspire |
| Kaleo, INC. | $30.77 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $28.16 | 2025 | Dawnzera |
| Stryker Corporation | $19.49 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $17.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rountree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.